









Markets
/
Stocks
/
nasdaq-espr
/

Esperion Therapeutics Inc

ESPR

2.640USD

-0.010-0.38%

Close 09/29, 16:00（ET）Quotes delayed by 15 min

528.41MMarket Cap

LossP/E TTM



Esperion Therapeutics Inc

2.640

-0.010-0.38%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Esperion Therapeutics Inc

Currency: USD Updated: 2025-09-29

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Esperion Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

76 / 174

Overall Ranking

203 / 4714

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

6.086

Target Price

+129.65%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Esperion Therapeutics Inc Highlights

StrengthsRisks

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 340.30% year-on-year.

Undervalued

The company’s latest PE is -5.27, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 118.70M shares, decreasing 29.12% quarter-over-quarter.

Held by Wasatch Global Investors

Star Investor Wasatch Global Investors holds 10.34M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-29

The company's current financial score is 7.74, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 82.39M, representing a year-over-year increase of 11.58%, while its net profit experienced a year-over-year increase of 79.45%.

Score

Industry at a Glance

Previous score

7.74

Change



Financials

5.11

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.60

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.11

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.43

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.44

Key Metrics

Free cash flow

No Data

Esperion Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-09-29

The company’s current valuation score is 7.58, which is higher than the Pharmaceuticals industry's average of 7.18. Its current P/E ratio is -5.27, which is -83.56% below the recent high of -0.87 and -7.58% above the recent low of -5.67.

Score

Industry at a Glance

Previous score

7.58

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 76/174

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-29

The company’s current earnings forecast score is 7.25, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Esperion Therapeutics Inc is 4.00, with a high of 16.00 and a low of 1.60.

Score

Industry at a Glance

Previous score

7.25

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Buy

Current Rating

6.086

Target Price

+129.65%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Esperion Therapeutics Inc

ESPR

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

AbbVie Inc

ABBV

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-29

The company’s current price momentum score is 6.97, which is higher than the Pharmaceuticals industry's average of 6.76. Sideways: Currently, the stock price is trading between the resistance level at 2.99 and the support level at 2.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.00

Change

-0.03

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.087

Neutral

RSI(14)

60.316

Neutral

STOCH(KDJ)(9,3,3)

43.391

Buy

ATR(14)

0.162

High Vlolatility

CCI(14)

7.732

Neutral

Williams %R

50.839

Neutral

TRIX(12,20)

0.863

Sell

StochRSI(14)

93.671

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

2.552

Buy

MA10

2.617

Buy

MA20

2.610

Buy

MA50

2.121

Buy

MA100

1.572

Buy

MA200

1.645

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-29

The company’s current institutional recognition score is 5.00, which is lower than the Pharmaceuticals industry's average of 6.28. The latest institutional shareholding proportion is 59.89%, representing a quarter-over-quarter decrease of 1.20%. The largest institutional shareholder is The Vanguard, holding a total of 11.72M shares, representing 5.81% of shares outstanding, with 1.86% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

13.34M

+1.89%

The Vanguard Group, Inc.

Star Investors

11.49M

-1.95%

Wasatch Global Investors Inc

Star Investors

10.93M

-55.35%

Two Seas Capital LP

6.93M

+11.23%

PenderFund Capital Management, Ltd.

2.00M

Marshall Wace LLP

3.63M

Geode Capital Management, L.L.C.

4.45M

+2.45%

Two Sigma Investments, LP

5.26M

-26.52%

Meditor Capital Management Limited

3.79M

State Street Global Advisors (US)

4.55M

+0.98%

Risk Assessment

Currency: USD Updated: 2025-09-29

The company’s current risk assessment score is 3.67, which is lower than the Pharmaceuticals industry's average of 5.10. The company's beta value is 0.95. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.